In contrast, both HIF-1α and CA9 were clearly expressed in all of the pre-Bev initial and post-Bev recurrent tumors (Figure 2H, 2I), suggesting that tumor oxygenation was improved with Bev treatment but returned to the original hypoxic condition in tumors refractory to Bev. The gene discussed is HIF1A; the disease is neoplasm.